Who can join
Studies for children and teens
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
468 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Sanofi
- Location
- Atlanta, GA + 4 other US sites
- Eligibility basics
- Ages 2–17
- Recruiting
Growth and Tolerance of Plant-based Enteral Formulas in Children Ages 12-17 Months.
Kate Farms Inc
- Location
- Columbus, OH
- Eligibility basics
- Ages 1–1
- RecruitingPhase 1/Phase 2
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Noveome Biotherapeutics, formerly Stemnion
- Location
- Little Rock, AR + 7 other US sites
- Eligibility basics
- Ages 0 mo–2 mo
- RecruitingPhase 2
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Ascendis Pharma A/S
- Location
- Saint Paul, MN + 2 other US sites
- Eligibility basics
- Ages 0 mo–2
- RecruitingPhase 3
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
- Location
- Washington D.C., DC + 1 other US site
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.
Novadip Biosciences
- Location
- Phoenix, AZ + 3 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 2
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
BioMarin Pharmaceutical
- Location
- Phoenix, AZ + 6 other US sites
- Eligibility basics
- Ages 0 mo–3
- RecruitingPhase 2
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
RECORDATI GROUP
- Location
- San Francisco, CA + 3 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1
Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents
Iterum Therapeutics, International Limited
- Location
- Little Rock, AR
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Halozyme Therapeutics
- Location
- Los Angeles, CA + 19 other US sites
- Eligibility basics
- Ages 12–17 · Men only
- Recruiting
AI-driven Total Parenteral Nutrition Platform
Takeoff41, Inc.
- Location
- Stanford, CA
- Eligibility basics
- Up to age 6 mo
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Birmingham, AL + 53 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
Amicus Therapeutics
- Location
- Gainesville, FL + 5 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery
Pacira Pharmaceuticals, Inc
- Location
- Indianapolis, IN + 4 other US sites
- Eligibility basics
- Ages 0 mo–6
- RecruitingPhase 1
Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)
Ionis Pharmaceuticals, Inc.
- Location
- Atlanta, GA + 2 other US sites
- Eligibility basics
- Ages 2–17 · Men only
- RecruitingPhase 2
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Amgen
- Location
- La Jolla, CA + 3 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 4
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
Bausch Health Americas, Inc.
- Location
- Garden Grove, CA + 3 other US sites
- Eligibility basics
- Ages 5–17
- Recruiting
Evaluation of Accuracy of the Owlet OSS 3.0 Sensor in the Neonatal Population
Owlet Baby Care, Inc.
- Location
- Birmingham, AL + 1 other US site
- Eligibility basics
- Ages 0 mo–1 mo
- Recruiting
Digital Wellness Nurse - FIT Families: Virtual Family Intervention for Adolescent Obesity
Machine and Human Interaction
- Location
- Charleston, SC
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
Pfizer
- Location
- Miami, FL + 4 other US sites
- Eligibility basics
- Ages 0 mo–17
- RecruitingPhase 3
InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
ONY
- Location
- Phoenix, AZ + 9 other US sites
- Eligibility basics
- Ages 7 mo–8 mo
- RecruitingPhase 2
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
Omeros Corporation
- Location
- San Diego, CA + 2 other US sites
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 4
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Upsher-Smith Laboratories
- Location
- La Jolla, CA + 5 other US sites
- Eligibility basics
- Ages 6–11
- Recruiting
Hyrax Vs. Invisalign Palatal Expander Clinical Study
Align Technology, Inc.
- Location
- Laguna Hills, CA + 3 other US sites
- Eligibility basics
- Ages 6–11
Questions
If I fit this group, will I qualify?
Not necessarily. Age and sex limits are only the first filter. Each study has its own inclusion and exclusion criteria, and the research team decides at screening.
Where do these age and sex limits come from?
From the eligibility section of each study’s official ClinicalTrials.gov record. We don’t infer eligibility from anything else.